Skip to content
GLP-1 Desk
Menu
Dispatch #43

Ro

A heavyweight platform with brand-name access — but opaque compounded pricing clouds its dispatch.

Visit RoAssume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we file on a provider reads the same either way.
Semaglutide
Not disclosed
Tirzepatide
Not disclosed
Coverage
Multi-state
Brand-name
Yes

Line Ro up against its closest alternatives. Or go one-on-one: Ro vs CoreAge Rx, Ro vs Hims & Hers and Ro vs Henry Meds.

Desk Score breakdown

Each of the six scored dimensions. See the methodology.

Price transparency62/100
State access84/100
Molecule range88/100
Onboarding speed78/100
Support responsiveness82/100
Licensing & trust84/100

What the Desk likes

  • Brand-name access and insurance navigation
  • Oral options available
  • Well-funded, stable platform

Where points come off

  • Compounded pricing not disclosed up front
  • Premium positioning limits price transparency score

The Desk's briefing — B−

Best for: Patients who want brand-name capability and insurance navigation support.

Ro ranks #43 of 508 providers scored — see #1, CoreAge Rx here.

Related dispatches

Everyone else here (24)

Pricing and verification reflect Ro's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on Ro's site. Not medical advice; see our disclosure.

← Back to The Desk